







Respiratory Medicine Unit

Introduction

(COPD) is a Chronic obstructive disease pulmonary with inflammatory heterogeneous disease distinct phenotypes. Patients with non-eosinophilic inflammation typically respond poorly to corticosteroid treatment¹ and have higher incidences of bacterial infection². *Haemophilus influenzae* is the most frequent bacterium detected in patients with COPD³. Here we investigate the effect of non-typeable Haemophilus influenzae (NTHi) infection on the expression of glucocorticoid which the receptor (GR), through corticosteroids act, in airway epithelial cells.

Hypothesis

NTHi infection downregulates the active GR alpha-isoform $(GR\alpha)$ and upregulates its inhibitory beta-isoform $(GR\beta)$ in airway epithelial cells, thereby inhibiting their response to corticosteroids.

Methods

- Beas2B cells, A549 cells and primary human bronchial epithelial cells were grown to 90% confluency in 24-well plates.
- Cells were treated with fluticasone propionate (FP) at 1 or 100nM for 2 hours prior to infection with 1.5 x 10^4 , 1 x 10^6 and 1.5 x 10⁷ CFU/ml NTHi (low, medium and high load respectively).
- 6 hours post-infection supernatants were collected and RNA extracted from cells by the E.Z.N.A. Total RNA Kit I Protocol.
- RNA was reverse transcribed using the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit.
- Quantitative PCR was carried out according to the Fast SYBR Green Master Mix Protocol to determine the relative cDNA levels of $GR\alpha$, $GR\beta$ and GAPDH in triplicate.
- Results were analysed by the Pfaffl method.
- Statistical analyses were performed with GraphPad Prism 7.03.

Glucocorticoid receptor α and β expression in airway epithelial cells infected with NTHi Parker L. J., Cane, J. L., Thulborn S. J., Bafadhel, M. Nuffield Department of Medicine, University of Oxford, UK

Results

FIGURE 1: Expression of GRα and GRβ in A549 and Beas2B cells treated with low, medium or high concentrations of NTHi and/or FP at 1nM or 100nM, relative to untreated (control) cells. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001



FIGURE 2: Expression of GRα and GRβ in HBECs treated with low, medium or high concentrations of NTHi and/or FP at 1nM or 100nM, relative to untreated (control) cells. *p<0.05, **p<0.01, ***p<0.001, ****p<0.001



FIGURE 2: In both the HBECs, GR α expression increased in conditions with the high NTHi concentration and pre-treatment with FP. Moreover, GRB expression was significantly increased in all conditions that included NTHi (e.g. for the high NTHi concentration and 100nM FP mean fold changes from control: +74.5 and +69.3 for healthy and COPD HBECs respectively, p<0.01).

FIGURE 1: NTHi had no consistent effect on $GR\alpha$ and $GR\beta$ expression in the Beas2B cells, though there was a small stepwise increase in $GR\alpha$ expression with FP treatment to 1nM to 100nM (mean fold changes from control +0.495 and +0.717 respectively, p<0.05). In the conditions with the high NTHi concentration in the A549 cells, GRa expression decreased (mean fold changes from control: -0.687, -0.549, and -0.725 for 0nM, 1nM and 100nM FP respectively, p<0.01) while GR β expression increased (mean fold changes from control: +1.78, +2.88, and +2.41 for 0nM, 1nM and 100nM FP respectively, p<0.001).

Conclusion

References

(2012) (2014)

Funded By

Oxford Biomedical Research Centre

All authors have no commercial support or relevant financial interests to disclose.



DEPARTMENT of

• GRβ expression significantly increased with the high NTHi concentration in A549 cells and with all three NTHi concentrations in both the healthy and COPD HBECs.

• This trend was apparent with and without pretreatment with FP, but was not observed in the Beas2B cells.

• GRα expression was not consistent between the different cell types, though both the healthy and COPD HBECs showed a similar response.

Bafadhel et al., Am J Respir Crit Care Med., 186(1), 48055 Bafadhel et al., Int J Chron Obstruct Pulmon Dis., 10, 1075-

1083 (2015) Mallia et al., Int J Chron Obstruct Pulmon Dis., 9, 1119-1132

NHS National Institute for Health Research